Gubra Services

Gubra enables you to progress your preclinical development for metabolic diseases with more certainty than any other research partner. We offer highly specialized services within five main disease areas.


Benefit from our extensive know-how in NASH and test your compound in our validated DIO NASH mouse models.

Learn more

Kidney (CKD)

Check out our novel rodent models of diabetic nephropathy.

Learn more

Heart (CVD)

Check out our novel rodent models of cardiovascular disease.

Learn more


Qualify and advance your assessment of novel compounds to treat type 2 diabetes and diabetic complications.

Learn more


Tap into our vast scientific experience with diet-induced obesity (DIO) models and other commercially available models.

Learn more

Customized services

We go beyond metabolism – see high-end models within neurodegenerative and gastrointestinal diseases.

Learn more

AI-assisted NASH histopathology using GHOST

At Gubra, we have developed the deep learning-based app GHOST (Gubra Histopathological Objective Scoring Technology) to automatically perform complete NAFLD Activity Score (NAS) and Fibrosis Staging in liver biopsies with additional quantitative metrics.

Why choose Gubra?

  • Proven track record with identification of new disease targets and new peptide drugs. The most advanced are currently in clinical development with pharma partner.
  • All projects are led by professional project leaders with strong scientific backgrounds and project management experience.
  • All data are generated in-house to ensure high data quality, integrity, speed and flexibility.
  • Our in-house in vivo facility is AAALAC accreditated.

Get in touch

Please get in touch if you are interested in discussing how to get started with your study.

Niels Vrang

Co-founder, Chairman of the Board
+45 3152 2651